Glycogen Storage Disease 0, Muscle
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Prevalence of exertional rhabdomyolysis in endurance horses in the Pacific Northwestern United States.
|
24579562 |
2015 |
Glycogen Storage Disease 0, Muscle
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Muscle glycogen storage disease 0 presenting recurrent syncope with weakness and myalgia.
|
21958591 |
2012 |
Glycogen Storage Disease 0, Muscle
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0.
|
17928598 |
2007 |
Glycogen Storage Disease 0, Muscle
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
|
|
|
Glycogen Storage Disease 0, Muscle
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Glycogen Storage Disease 0, Muscle
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
Glycogen Storage Disease 0, Muscle
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Glycogen Storage Disease 0, Muscle
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Glycogen Storage Disease
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
|
|
|
Cardiomyopathies
|
0.110 |
Biomarker
|
group |
BEFREE |
Children with abnormal cardiac responses to increased workloads as well as those with defined myocardial disease should therefore be tested for GYS1 deficiency.
|
19699667 |
2009 |
Cardiomyopathies
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
Cerebrovascular accident
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
Left Ventricular Hypertrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
P mitrale (finding)
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Left atrial hypertrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Impaired exercise tolerance
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Tonic - clonic seizures
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Decreased muscle glycogen content
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
In males the GYS1 XbaI T-allele (hazard ratio (HR) 1.9 [1.2-2.9]), T2D (2.5 [1.7-3.8]), earlier CV events (1.7 [1.2-2.5]), physical inactivity (1.9 [1.2-2.9]) and smoking (1.5 [1.0-2.3]) predicted CV mortality.
|
17356695 |
2007 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the M416V polymorphism of GYS1 gene is not associated with insulin resistance in type 2 diabetes.
|
12870167 |
2003 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The Met416Val polymorphism of GYS1 gene was not significantly associated with the risk of type 2 DM (adjusted OR = 1.67; 95% CI: 0.73 - 3.81, P = 0.223).
|
12411100 |
2002 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
We conclude that 1) insulin stimulates GYS1 mRNA expression; and 2) impaired stimulation of GYS1 gene expression by insulin in patients with type 2 diabetes is acquired and most likely is secondary to chronic hyperglycemia.
|
10770201 |
2000 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The A2 allele of the XbaI polymorphism in the GYS1 confers an increased susceptibility to different features of the metabolic syndrome and Type II diabetes.
|
10447527 |
1999 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
These findings indicate that the M416V mutation of the GYS1 gene is one of the factors contributing to the insulin resistance in the Japanese population and may play some role in the pathogenesis of NIDDM.
|
9267990 |
1997 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The glycogen synthase gene (GYS1), which encodes the rate-limiting enzyme for glycogen synthesis, is a promising candidate gene for NIDDM.
|
9389424 |
1997 |